About the Company
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MRTX News
Bristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.8B buyout
Two months after closing its multibillion-dollar acquisition of Mirati Therapeutics, Bristol Myers Squibb is bidding adieu to ...
Bristol Myers to Buy Mirati Therapeutics for $4.8 Billion
(Bloomberg) -- Bristol-Myers Squibb Co. agreed to buy drugmaker Mirati Therapeutics Inc. for $4.8 billion to expand its aging portfolio of cancer drugs. Mirati shareholders will receive $58 a ...
Mirati Therapeutics files patent for inhibitors of KRAS g12d
Discover Mirati Therapeutics' groundbreaking patent for compounds inhibiting KRas G12D activity in cancer cells. Learn about the specific structures, methods, and potential impact on cancer treatment.
Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B
Bristol Myers Squibb BMY announced that it will acquire commercial-stage oncology company Mirati Therapeutics, Inc.MRTX for $58.00 per share in cash, amounting to a total equity value of $4.8 ...
What’s Next For Mirati Therapeutics Stock After A 20% Rise In A Month?
Opinions expressed by Forbes Contributors are their own. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using the last ten years’ data After moving 27% or more over five days ...
Rocket Pharmaceuticals Names Aaron Ondrey CFO
Late-stage biotechnology company Rocket Pharmaceuticals, Inc. (RCKT), Tuesday announced the appointment of Aaron Ondrey, as Chief ...
Bristol Myers to buy cancer specialist Mirati for up to $5.8 billion
Bristol Myers will pay up to $5.8 billion for cancer-treatment specialists Mirati, the most recent ... Turning Point Therapeutics, which focuses on oncogenesis, or the process in which healthy ...
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...
Mirati Therapeutics Inc (26M.BE)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Cara Therapeutics Inc CARA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
ATXI Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product ...
TNGX Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein ...
Loading the latest forecasts...